Plain-English translation of NCT05952934 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing an experimental vaccine called Candin® to see if it can help prevent head and neck cancer from coming back after you've finished your primary treatment (surgery, radiation, chemotherapy, or immunotherapy). The vaccine works by stimulating your immune system to recognize and fight any remaining cancer cells. Researchers want to know if this treatment is safe and effective in reducing the chance of cancer recurrence.
Even after successful treatment, head and neck cancer can sometimes return, which is a serious concern for patients and doctors. This medication is being studied because early evidence suggests that training the immune system to target cancer cells might help keep cancer from coming back.
You likely qualify if…
You likely don't qualify if…
You would receive a total of 7 injections over approximately 2 years—one injection every 3 weeks for the first 4 doses, then one injection every 3 months for the remaining doses. Each injection is small (0.5 mL) and given under the skin on your arm or leg. You'll have multiple follow-up visits for blood tests and samples (oral rinse and stool) to check how your immune system is responding. There's a 3-in-4 chance you'll receive the actual vaccine and a 1-in-4 chance you'll receive a placebo (saline injection), but neither you nor your doctor will know which you're getting during the study.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
United States